CardioWise heart analysis software combined with cardiac MRI is a single diagnostic test that is able to provide quantitative analysis of the myocardium, arteries and valves with an unprecedented level of detail.
Fayetteville, Arkansas (PRWEB) February 28, 2013
CardioWise, Inc. received a $150,000 Phase I Small Business Innovation Research grant from the National Science Foundation to support the development and commercialization of a non-invasive analysis method for detection of heart disease. This software program is uniquely capable of analyzing the movement of the heart captured by cardiac MRI images. The parts of the heart with damage have abnormal movement patterns and the post-MRI analysis clearly shows where and to what degree the muscle has been damaged. Unlike many other diagnostic tests, MRI with the CardioWise analysis poses no risk to the patient, and subsequent tests can be accurately compared to previous tests to see how treatment is working. Ultimately, this diagnostic method may help doctors decide how soon or if a patient requires an intervention such as a drug, stent or surgery.
Every day, 2400 people in the United States die of heart disease. The associated yearly cost of caring for heart patients has risen above $300 billion (American Heart Association, 2010). For most people, the first indication of heart disease is a heart attack. Heart failure, the consequence of heart attacks or other heart disease, is currently the most rapidly increasing clinical manifestation of cardiac disease in the United States. Improvements in diagnostic and therapeutic heart disease intervention have the potential to profoundly impact patients and the U. S. healthcare system.
About CardioWise, Inc.:
CardioWise™ is commercializing patent-pending, non-invasive Cardiac Magnetic Resonance Imaging (cMRI) analysis software that produces a quantified 3D image model of the human heart, called Multiparametric Strain (MPS™) heart analysis. CardioWise heart analysis software combined with cardiac MRI is a single diagnostic test that is able to provide quantitative analysis of the myocardium, arteries and valves with an unprecedented level of detail. It has the opportunity to become the new gold standard of care for heart health analysis. CardioWise™ is a VIC Technology Venture Development™ portfolio company.